Vita Life Sciences Limited · ASX:VLS

Vita Life Sciences — FY2011 Earnings Presentation

16 slides from Vita Life Sciences's earnings presentation, February 2012

  1. Slide 1: Vita Life Sciences Limited 2011 Full Year Results

    Vita Life Sciences Limited 2011 Full Year Results ASX Code: VSC

  2. Slide 2: Vita Life Sciences Ltd

    Vita Life Sciences Ltd Pharmaceutical and healthcare Over-The-Counter business Wide range of supplements, vitamins, minerals, meal replacement, sports nutrition and herbal care “Herbs of Gold” throughout Australia and China “VitaHealth” and “VitaLife” throughout Asia 1

  3. Slide 3: Objectives

    Objectives Continue to grow Established business units Strong market position in Australia, Malaysia and Singapore Objective: To continue past growth trend of ~15% pa Expansion through New business in Asia Objective: an “all Asia footprint” Sales made in China, Indonesia, Thailand and Vietnam accoun

  4. Slide 4: Group Objective – an "all Asia Footprint"

    Group Objective – an “all Asia Footprint” Established business units: Australia, Malaysia and Singapore New business units: China, Indonesia, Thailand and Vietnam Long term expansion goal 3

  5. Slide 5: 2011 Results Overview

    2011 Results Overview Income Statement 2011 2010 for year ended (A$ million) (A$ million) % Change Sales 24.3 21.0 15.6% Other income 0.2 6.1 -97% Operating expenses (22.9) (22.3) 3% EBITDA 1.6 5.0 -69% Depreciation & amortisation (0.1) (0.1) -22% EBIT 1.5 4.9 -70% Interest expense (0.1) (0.3) -70%

  6. Slide 6: Normalised Profit

    Normalised Profit Income Statement ($ m) 2011 2010 % Change EBIT 1.5 4.9 -70% Add / (less): Pan Case net receipts / (costs) - (4.1) -100% Normalised EBIT 1.5 0.8 83% Interest expense (0.2) (0.3) -43% Income tax expense (0.2) (0.2) 14% Normalised net profit after tax 1.1 0.4 219% Normalised EPS 2.0 c

  7. Slide 7: Sales Trend, Normalised EBIT and Debt

    Sales Trend, Normalised EBIT and Debt Year 2007 2008 2009 2010 2011 Events Relisted on ASX Focus on sales Group profitable Group profitable Group debt free and growth profitable 30.0 25.0 20.0 A$ million 15.0 10.0 5.0 - 2007 2008 2009 2010 2011 (5.0) Sales ($'m) 12.4 15.0 17.7 21.0 24.3 Normalised (

  8. Slide 8: Gaining Momentum

    Gaining Momentum Group: Sales growth 61.8% over the 3 years to December 2011 Group: Sales grew 15.6% in 2011 Established business units: sales increased by 11.3% in 2011 New business units: Thailand: Sales grew 58% in 2011. Malaysia: Multi-Level Marketing business unit grew 66.8% in 2011 contributin

  9. Slide 9: Group Sales Revenue (in A$)

    Group Sales Revenue (in A$) • Sales in Australia up 14.1% (2010 :13.4%) • Sales in Malaysia up 13.4% (2010: 13.1%) • Sales in Singapore down 5.3% (2010: up 12.5%) 8

  10. Slide 10: Established business units Sales Revenue

    Established business units Sales Revenue (in local currency) Malaysia local currency sales 25.0 • Sales in Malaysia up Malaysian Ringgit (million) 20.0 21.2 15.0 17.6 20.4% (2010: 20.2%) 14.6 10.0 5.0 - 2009 2010 2011 Singapore local currency sales 6.0 5.0 • Sales in Singapore up Singapore dollar (m

  11. Slide 11: Sales Revenue-Segment

    Sales Revenue-Segment 25,000,000 20,000,000 Australia remains the largest contributor at 45% (2010:45%) 15,000,000 Malaysia’s contribution to revenue Others is growing, with 37% of Group Singapore 10,000,000 Malaysia sales in 2011 (2010: 34%) Australia New markets China, Indonesia, 5,000,000 Thailan

  12. Slide 12: Group Balance Sheet

    Group Balance Sheet At 31 December ($ m) 2011 2010 Current assets 10.9 12.2 Non-current assets 2.4 2.3 Total assets 13.4 14.5 Current liabilities (4.4) (6.4) Non-current liabilities (0.0) (0.0) Total liabilities (4.4) (6.4) Net assets 9.0 8.1 Cash balance of $3.6 m (2010: $0.5m) Net assets increased

  13. Slide 13: Award Winning Brands in Malaysia

    Award Winning Brands in Malaysia 12

  14. Slide 14: Investment Division

    Investment Division Group has a $1.0m (6.3%) and 20.1% profit share in a property project in Malaysia 35% of total development sold by end 2011 Investment is positive cash flow and self-funded 13

  15. Slide 15: Health Division Outlook-2012

    Health Division Outlook-2012 Sales trends expected to continue EBIT and profit forecast to be higher than 2011 Strong focus on expanding customer base and business development in New business units after initial set up years Continue to reinvest 30% of operating profits from Established business uni

  16. Slide 16: Closing Thank You

    Closing Thank You 28 February 2012 15

Vita Life Sciences — FY2011 Earnings Presentation on 6ix